Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Tokyo District Court Dismisses Takeda’s Actos Litigation Against 10 Companies; No Appeal Planned
March 4, 2013
- Japan’s Average Drug Price is 1.44 Times Higher than Europe: MHLW Tally
March 1, 2013
- MHLW’s Health and Medical Strategy HQ Aims to Draft a Final Plan by May
February 28, 2013
- Pharmacies’ Generic Drug Dispensing Rate Rises to 29.4%: Survey Reported to CSIMC
February 28, 2013
- 5 Years Too Long to Achieve Reference Generic Share Target of 60%: Bill Payer Reps at CSIMC Subcommittee
February 28, 2013
- Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium
February 28, 2013
- Participation in TPP Talks “Will Not Damage” Japan’s Universal Health Insurance System: Health Minister Tamura
February 27, 2013
- PAFSC’s 2nd Committee Recommends Approval for CMIC’s Acute Porphyria Treatment
February 27, 2013
- JMACCT Revamps Database of Clinical Trial Institutions; Details Now Available Online
February 27, 2013
- MHLW Launches HQ to Promote Health and Medical Strategy
February 27, 2013
- Doctors' Average Monthly Wage Reaches 789,300 Yen in 2012, MHLW Survey Shows
February 25, 2013
- Govt Launches New Office of Health and Medical Strategy
February 25, 2013
- Ruling Parties’ Commission on Reduced Consumption Tax Rate System to Issue Interim Report This Summer
February 22, 2013
- MHLW Plans to Revise Ordinance within 2 to 3 Years to Allow Electronic Prescribing
February 22, 2013
- About 60% of Prefectures Won't Set Generic Share Targets in Medical Expenditure Optimization Plans
February 22, 2013
- MHLW to Examine Online OTC Drug Sales after Top Court Ruling
February 22, 2013
- EAD Director Kamata Calls for Early Price Settlements at Municipal Hospitals
February 21, 2013
- MHLW Eager to Submit Bill to Amend PAL to Diet by Summer, Councilor Hirayama Says
February 21, 2013
- Tokyo’s Katsushika Ward Allies with Wholesalers in Drug Procurement during Disasters
February 21, 2013
- Private-sector Members of Industrial Competitiveness Council Divided on Measures to Strengthen Innovation
February 20, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…